OncoSil Patent Expiry – Real Threat or Overstated Concern?, page-6

Thanks mate — appreciate the kind words.To be honest, there’s just not a lot of meaningful news to report right now. We’re in a bit of a holding pattern while we wait on the TRIPP-FFX and PANCOSIL trials to wrap up, ongoing HDE discussions with the FDA, the TGA application here in Australia, regulatory progress in the Middle East, and for the G-BA in Germany to really crank up.I’d love to get more visibility on how many procedures have actually been done and in which hospitals — but for now I’m just hanging out for the March quarterly to see if we’re building on the commercial momentum from late last year.Funding is definitely a concern. Aside from market conditions, I reckon the uncertainty around runway beyond June/July is probably one of the biggest things holding the share price back. That said, one silver lining for now is that OncoSil’s current revenue isn’t impacted by US tariffs — though that’ll probably change further down the track.